PepGen Reports Positive Data from its Phase 1 Study of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy September 28, 2022 at 8:00 AM EDT Click here for webcast Supporting Materials PepGen’s Phase 1 Trial Results of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy 5.2 MB
